Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure

被引:204
作者
Gislason, Gunnar H. [1 ]
Rasmussen, Jeppe N. [2 ]
Abildstrom, Steen Z. [1 ,2 ]
Schramm, Tina K. [1 ,2 ]
Hansen, Morten L. [1 ]
Fosbol, Emil L. [1 ]
Sorensen, Rikke [1 ]
Folke, Fredrik [1 ]
Buch, Pernille [1 ]
Gadsboll, Niels [7 ]
Rasmussen, Soren [2 ]
Poulsen, Henrik E. [3 ,5 ]
Kober, Lars [4 ,5 ]
Madsen, Mette [6 ]
Torp-Pedersen, Christian [1 ,5 ]
机构
[1] Gentofte Univ Hosp, Dept Cardiol, DK-2900 Hellerup, Denmark
[2] Univ Copenhagen Hosp, Rigshosp, Natl Inst Publ Hlth, DK-2100 Copenhagen, Denmark
[3] Univ Copenhagen Hosp, Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
[4] Univ Copenhagen Hosp, Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Publ Hlth Res Inst, Copenhagen, Denmark
[7] Roskilde Cty Psychiat Hosp Fjorden, Dept Med, Koge, Denmark
关键词
SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; MYOCARDIAL-INFARCTION; CYCLO-OXYGENASE-2; INHIBITORS; BLOOD-PRESSURE; RISK; EVENTS; POPULATION; CELECOXIB; ROFECOXIB; OUTCOMES;
D O I
10.1001/archinternmed.2008.525
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug ( NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF. Methods: We identified 107 092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models. Results: A total of 36 354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60 974 (56.9%) died, and 8970 (8.4%) and 39 984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results. Conclusions: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 46 条
[1]   Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].
Antman, Elliott M. ;
Bennett, Joel S. ;
Daugherty, Alan ;
Furberg, Curt ;
Roberts, Harold ;
Taubert, Kathryn A. .
CIRCULATION, 2007, 115 (12) :1634-1642
[2]   Cyclooxygenase inhibition and cardiovascular risk [J].
Antman, EM ;
DeMets, D ;
Loscalzo, J .
CIRCULATION, 2005, 112 (05) :759-770
[3]   Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J].
Aw, TJ ;
Haas, SJ ;
Liew, D ;
Krum, H .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) :490-496
[4]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[5]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[6]   The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction [J].
Brophy, J. M. ;
Levesque, L. E. ;
Zhang, B. .
HEART, 2007, 93 (02) :189-194
[7]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[8]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[9]   Relation of loop diuretic dose to mortality in advanced heart failure [J].
Eshaghian, Shervin ;
Horwich, Tamara B. ;
Fonarow, Gregg C. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12) :1759-1764
[10]   Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib [J].
Farkouh, M. E. ;
Greenberg, J. D. ;
Jeger, R. V. ;
Ramanathan, K. ;
Verheugt, F. W. A. ;
Chesebro, J. H. ;
Kirshner, H. ;
Hochman, J. S. ;
Lay, C. L. ;
Ruland, S. ;
Mellein, B. ;
Matchaba, P. T. ;
Fuster, V. ;
Abramson, S. B. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :764-770